JP6328146B2 - 神経変性およびその他の疾患の治療用組成物および方法 - Google Patents

神経変性およびその他の疾患の治療用組成物および方法 Download PDF

Info

Publication number
JP6328146B2
JP6328146B2 JP2015556185A JP2015556185A JP6328146B2 JP 6328146 B2 JP6328146 B2 JP 6328146B2 JP 2015556185 A JP2015556185 A JP 2015556185A JP 2015556185 A JP2015556185 A JP 2015556185A JP 6328146 B2 JP6328146 B2 JP 6328146B2
Authority
JP
Japan
Prior art keywords
sulfasalazine
pharmaceutical composition
certain embodiments
patient
formulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015556185A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016507526A (ja
JP2016507526A5 (enExample
Inventor
サディアス・クロムウェル・リーダー
マーク・ウェイド・ムーア
ダグラス・アラン・ロレンツ
デイビッド・キース・ライオン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glialogix Inc
Original Assignee
Glialogix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glialogix Inc filed Critical Glialogix Inc
Publication of JP2016507526A publication Critical patent/JP2016507526A/ja
Publication of JP2016507526A5 publication Critical patent/JP2016507526A5/ja
Application granted granted Critical
Publication of JP6328146B2 publication Critical patent/JP6328146B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2015556185A 2013-02-01 2014-01-31 神経変性およびその他の疾患の治療用組成物および方法 Expired - Fee Related JP6328146B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361759933P 2013-02-01 2013-02-01
US61/759,933 2013-02-01
US201361780340P 2013-03-13 2013-03-13
US61/780,340 2013-03-13
PCT/US2014/014290 WO2014121137A2 (en) 2013-02-01 2014-01-31 Compositions and methods for the treatment of neurodegenerative and other diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018079284A Division JP2018123159A (ja) 2013-02-01 2018-04-17 神経変性およびその他の疾患の治療用組成物および方法

Publications (3)

Publication Number Publication Date
JP2016507526A JP2016507526A (ja) 2016-03-10
JP2016507526A5 JP2016507526A5 (enExample) 2017-02-23
JP6328146B2 true JP6328146B2 (ja) 2018-05-23

Family

ID=50382538

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015556185A Expired - Fee Related JP6328146B2 (ja) 2013-02-01 2014-01-31 神経変性およびその他の疾患の治療用組成物および方法
JP2018079284A Pending JP2018123159A (ja) 2013-02-01 2018-04-17 神経変性およびその他の疾患の治療用組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018079284A Pending JP2018123159A (ja) 2013-02-01 2018-04-17 神経変性およびその他の疾患の治療用組成物および方法

Country Status (10)

Country Link
US (5) US9597339B2 (enExample)
EP (1) EP2950797B1 (enExample)
JP (2) JP6328146B2 (enExample)
KR (1) KR20150139830A (enExample)
CN (1) CN105163735B (enExample)
AU (2) AU2014212109B2 (enExample)
CA (1) CA2899032A1 (enExample)
ES (1) ES2752021T3 (enExample)
IL (1) IL240206A0 (enExample)
WO (1) WO2014121137A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018123159A (ja) * 2013-02-01 2018-08-09 グリアロジクス・インコーポレイテッドＧｌｉａｌｏｇｉｘ， Ｉｎｃ． 神経変性およびその他の疾患の治療用組成物および方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102364840B1 (ko) * 2014-11-05 2022-02-18 삼성전자주식회사 신경세포의 탈수초화와 연관된 질환을 치료하기 위한 약학적 조성물 및 그를 이용하는 방법
US20160199393A1 (en) * 2015-01-08 2016-07-14 China Medical University Methods of treating brain ischemia or hypoxia
ES2650175B1 (es) * 2016-04-15 2019-02-04 Servicio Andaluz De Salud Tratamiento de enfermedades neurodegenerativas
CN109414507A (zh) * 2016-04-26 2019-03-01 美国圣路易斯大学 用于预防和治疗神经退行性疾病的高度选择性腺苷a3受体亚型激动剂
US20180110760A1 (en) * 2016-10-21 2018-04-26 Glialogix, Inc. Compositions and methods for the treatmentof neurodegenerative and other diseases
US10473672B2 (en) * 2017-02-09 2019-11-12 Kaohsiung Chang Gung Memorial Hospital Methods for diagnosing and treating Alzheimers disease using G72 protein and SLC7A11 mRNA as biomarkers
US20230210871A1 (en) * 2017-10-12 2023-07-06 The Limited Company Research And Development Company "Medbiopharm" Use of sulfasalazine as an inhibitor of the formation of advanced glycation end products
JP6603815B2 (ja) * 2017-11-21 2019-11-06 積水化学工業株式会社 皮膚外用剤

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2396145A (en) 1940-12-14 1946-03-05 Pharmscia Ab Heterocyclic sulphonamido azo compounds
FR2608988B1 (fr) 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
HUT77373A (hu) 1994-09-29 1998-03-30 Andaris Limited Porlasztva szárított mikrorészecskék gyógyszerészeti hordozóként
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
ITMI962356A1 (it) 1996-11-13 1998-05-13 Uni Degli Studi Di Brescia D I Uso di composti derivati da molecole ad attivita' antinfiammatoria di tipo non steroideo per la prevenzione e il trattamento di
WO1998031346A1 (en) 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
CA2336139C (en) 1998-06-24 2008-10-14 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
EP1107743B1 (en) 1998-08-25 2007-06-27 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
KR100417623B1 (ko) 2000-03-28 2004-02-05 주식회사 뉴로테크 뇌질환 예방 및 치료용 조성물
CA2307278A1 (en) 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
WO2003063822A2 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
EP1469830A2 (en) 2002-02-01 2004-10-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
US8748445B2 (en) 2004-10-27 2014-06-10 The Uab Research Foundation Methods for treating glioma
US8034765B2 (en) 2005-08-31 2011-10-11 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
US20070053869A1 (en) 2005-09-02 2007-03-08 Yuichi Sugiyama Formulation and method for enhancement of gastrointestinal absorption of pharmaceutical agents
GB0602123D0 (en) * 2006-02-02 2006-03-15 Novartis Ag Organic compounds
CA2637255C (en) 2006-02-02 2018-06-12 Novartis Ag 40-o-(2-hydroxyethyl)-rapamycin for treating tuberous sclerosis disorders
US7964585B2 (en) 2006-03-14 2011-06-21 Case Western Reserve University Composition and method of treating peripheral neuropathy
KR101468053B1 (ko) 2006-08-31 2014-12-02 앱탈리스 파마테크, 인코포레이티드 약 염기성 약물의 고용체를 포함하는 약물 전달 시스템
WO2008135828A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2009073215A1 (en) 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
EP2259777A2 (en) * 2008-02-28 2010-12-15 BIAL - Portela & Ca., S.A. Pharmaceutical composition for poorly soluble drugs
SI2113254T1 (sl) * 2008-04-28 2013-01-31 Txcell Sestave za zdravljenje vnetnih avtoimunskih stanj
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
EP2411137B1 (en) 2009-03-27 2016-09-07 Bend Research, Inc. Spray-drying process
US9084976B2 (en) 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
EP2611530B1 (en) 2010-09-03 2019-01-16 Bend Research, Inc. Spray-drying apparatus and methods of using the same
WO2013115965A1 (en) 2012-01-31 2013-08-08 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
US9597339B2 (en) * 2013-02-01 2017-03-21 Glialogix, Inc. Compositions and methods for the treatment of neurodegenerative and other diseases
CA2935307C (en) 2013-12-31 2023-05-09 Ascendia Pharmaceuticals, Llc Pharmaceutical compositions for poorly water-soluble compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018123159A (ja) * 2013-02-01 2018-08-09 グリアロジクス・インコーポレイテッドＧｌｉａｌｏｇｉｘ， Ｉｎｃ． 神経変性およびその他の疾患の治療用組成物および方法

Also Published As

Publication number Publication date
JP2018123159A (ja) 2018-08-09
US20170079991A1 (en) 2017-03-23
CA2899032A1 (en) 2014-08-07
US9980978B2 (en) 2018-05-29
US20170165279A1 (en) 2017-06-15
CN105163735B (zh) 2018-12-11
KR20150139830A (ko) 2015-12-14
WO2014121137A3 (en) 2014-11-27
JP2016507526A (ja) 2016-03-10
US10398713B2 (en) 2019-09-03
ES2752021T3 (es) 2020-04-02
EP2950797B1 (en) 2019-09-11
EP2950797A2 (en) 2015-12-09
AU2018222921A1 (en) 2018-09-20
US9918997B2 (en) 2018-03-20
AU2014212109B2 (en) 2018-05-31
US9974798B2 (en) 2018-05-22
US20140221321A1 (en) 2014-08-07
AU2014212109A1 (en) 2015-08-06
US9597339B2 (en) 2017-03-21
WO2014121137A2 (en) 2014-08-07
IL240206A0 (en) 2015-09-24
CN105163735A (zh) 2015-12-16
US20190015431A1 (en) 2019-01-17
US20170079990A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
JP6328146B2 (ja) 神経変性およびその他の疾患の治療用組成物および方法
KR102014883B1 (ko) 근위축성 측삭 경화증 치료용 신규 조성물
JP5175740B2 (ja) ピルフェニドン療法に付随する有害事象を低減する方法
EP3645003A2 (en) Combination and uses and treatments thereof
CN114727976A (zh) PPAR-δ激动剂在肾脏疾病治疗中的用途
US20200009118A1 (en) Compositions and methods for the treatmentof neurodegenerative and other diseases
KR20240162560A (ko) 에플로르니틴 및 설린닥, 고정된 용량 조합 제제
CN113347975B (zh) 用于治疗侵蚀性手骨关节炎的孟鲁司特
ES2729208T3 (es) Terapia basada en baclofeno y acamprosato de trastornos de degeneración macular
Panakanti et al. Impact of excipient interactions on drug bioavailability from solid dosage forms
EP3454898B1 (en) Drug combinations for reducing cell viability and/or cell proliferation
AU2021383325A9 (en) Use of pridopidine and analogs for treating rett syndrome
US20240100011A1 (en) Pediatric formulations of ferric citrate
RU2799049C2 (ru) Способы лечения изменений поведения
KR20250152109A (ko) 종양학적 병리 및 신경병증성 통증 치료에 사용하기 위한 2-하이드록시-옥타데센-9-시스-오에이트
WO2025168614A1 (en) Pharmaceutical compositions comprising azd0780
TW202448432A (zh) 肌萎縮性側索硬化症（ａｌｓ）的治療

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180305

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180320

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180417

R150 Certificate of patent or registration of utility model

Ref document number: 6328146

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees